At Sunovion, we are advancing therapies to tackle some of the most challenging psychiatric and neurological disorders that impact the lives of millions of people 在世界范围内. 作为一个 patient-centered company, we focus on improving the quality of life for those living with serious CNS conditions. 在一个 decade, we have introduced several new treatment options and will continue expanding our portfolio to enable better 我们所服务的对象的结果. 今天创新，明天更健康.

Sunovion, innovation today, healthier tomorrow 标志.

我们的使命,
愿景 & 值

Our mission, vision and values are foundational to our 目的和推动我们的创新药物. 这些原则 inspire our culture and foster collaboration, trust, and a 热情为患者服务. 我们努力为 society through the novel application of science and medicine to support a healthy future for people around the 全球.

Artwork illustrating the foundational Sunovion mission, vision and values.

Sunovion 通过数字

Historically, have been ranked fastest growing 名列前茅.S. 制药公司*

前20名

Historically, have been ranked fastest growing 名列前茅.S. 制药公司*

全球800多名员工

800+

员工 在世界范围内

32,000个员工志愿者小时

32K+

员工 志愿者 小时 10年以上

* 查看源页面

我们的人民
和文化

Bringing together diverse experiences, our people are the cornerstone of Sunovion and shape our culture while advancing 我们的成功. With their combined talent and dedication, they 作为一个团队，团结，合作，赢得胜利.

Three coworkers laughing with one of their peers.

多样性 & 包容

Sunovion is committed to embracing diversity and inclusion 我们所做的一切. 我们的团队带来了各种各样的 experiences and approaches to work, allowing us to offer our patients the most innovative and effective solutions.

Teammates in a meeting around a table and laughing together.

社会 责任

Because we believe in supporting the communities where we live and work, we partner with local organizations who share 我们的激情. Far more than a commitment, we consider it our responsibility to make our world stronger and healthier.

A woman supporting her community by providing local support on a farm.

我们的历史 创新的

For more than a decade, we have innovated clinical advances and new treatment options for people living with serious psychiatric and neurological conditions. We continue to develop and support leading advocacy programs and community initiatives focused on improving 卫生保健. 以医学科学的遗产为基础 discoveries and treatments for patients remains our 目标.

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

2021

首席执行官安东尼•洛贝尔，m.s.D. 签署“CEO行动计划” 多样性 & “包容”继续我们的承诺 推进D&在工作场所

太阳答案被命名为J.D. 能力认证 客户服务计划 (SM)

Sunovion，住友制药公司.有限公司 and Otsuka enter 在世界范围内 development and commercialization collaboration

2020

Sunovion named Gold Stevie® Winner and "Employer of the Year" for Great Employers in The Stevie® 奖

FDA approves KYNMOBI® (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes 与帕金森病(PD)相关

KYNMOBI®在美国上市.S.

新英格兰医学杂志 发布 pivotal results evaluating SEP-363856 for treatment of 精神分裂症

加拿大卫生部批准KYNMOBI®

太阳之星的答案被命名为J.D. 电力认证客户 服务程序SM 第三次了

2019

Sunovion 手在! 年度迪士尼3彩乐园服务 Program contributes more than 30,000 employee volunteer 小时 in 439 projects in eight years to community organizations and relief efforts

太阳之星的答案被命名为J.D. 电力认证客户 服务程序SM 第二次

FDA接受APL-130277重新提交的NDA

SEP-363856 receives FDA Breakthrough Therapy 指定

太阳和高等数学 & 科学院 (AMSA) Charter School begin STEM partnership to 激励下一代创新者

2018

Sunovion 手在! 迪士尼3彩乐园服务计划 contributes 25,000+ volunteer 小时 in 415+ projects 在七年内

Receives Corporate 社会 责任 Award, United 《迪士尼3彩乐园》，2018年

Receives FDA approval of supplemental NDA for use of Latuda® in treatment of bipolar depression in 儿科患者

Lonhala®Magnair®在美国上市.S.

Health Canada approves Latuda® to treat adolescents 双相抑郁症患者

Health Canada Approves Aptiom® (eslicarbazepine 醋酸盐)作为单一疗法

Health Canada Approves of Aptiom® (eslicarbazepine 醋酸盐)作为辅助治疗





2017

Receives FDA approval for Latuda® to treat adolescents 患有精神分裂症

sunvion Answers变成了J.D. 能力认证 客户服务计划SM

Establish partnership with Boston Red Sox and Red Sox 基金会

Health Canada approves Latuda® to treat adolescents 患有精神分裂症

Receives FDA approval for Aptiom® for expanded indication to treat 部分性癫痫发作 in children 和青少年

Receives FDA approval for Lonhala® Magnair® Inhalation 慢性阻塞性肺病的治疗方案

2016

sunnovion在增长速度上排名第二 制药公司*

“Lead the Way to a Healthier World” established as the 公司的愿景

Receives Corporate 责任 Award, United Way of 三县,2016年

Complete acquisition of Cynapsus Therapeutics and its 产品的候选人

2015

Honored with The JED 基金会 Corporate Leadership 精神卫生领导奖

Won SCRIP Award for Management Team of the Year

Received Silver Stevie Award: Global Clinical Development Organization, American Business 奖 (Stevies)

Received FDA approval for Aptiom® as monotherapy for 部分性癫痫发作

2014

Health Canada approves Aptiom® as once-daily 辅助治疗

Aptiom®在美国上市.S.

2013

FDA approves Latuda® as monotherapy and adjunctive 成人双相抑郁症的治疗

Receives FDA approval of Aptiom® (eslicarbazepine acetate) as 辅助治疗 of partial-onset 癫痫发作

Becomes inaugural member of Massachusetts Life 科学中心神经科学联盟

2012

Complete acquisition of Elevation Pharmaceuticals

发布年度 手在! 迪士尼3彩乐园服务 program to give back where employees live and work

Health Canada approves Latuda® for 精神分裂症 in 成年人

2011

宣布与CARE公司合作.，国际 humanitarian agency, to help improve the health and 那些需要帮助的人的生命

Latuda® becomes available for the treatment of adult 精神分裂症患者

2010

Sunovion is established (October 2010) following the Sepracor公司整合. 和大日本住友 美国制药公司.，前美国.S. 的操作 Sunovion’s parent company Sumitomo Dainippon Pharma Co.有限公司.

The FDA approves Latuda® (lurasidone HCl) for the treatment of adult 精神分裂症患者